Italia markets close in 2 hours 5 minutes

Cerevel Therapeutics Holdings, Inc. (CERE)

NasdaqCM - NasdaqCM Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
42,22-0,16 (-0,37%)
In data: 10:24AM EDT. Mercato aperto.

Cerevel Therapeutics Holdings, Inc.

222 Jacobs Street
Suite 200
Cambridge, MA 02141
United States
844 304 2048
https://www.cerevel.com

Settore/iHealthcare
SettoreBiotechnology
Impiegati a tempo pieno334

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Dr. N. Anthony Coles Jr., M.P.H.Executive Chairman1,14MN/D1960
Mr. Mark BodenraderVP of Finance & Chief Accounting Officer496,17kN/D1973
Dr. John J. Renger Ph.D.Chief Scientific Officer779,75k10,44M1969
Dr. Ramiro Sanchez M.D.Chief Medical Officer805,13kN/D1961
Mr. Ronald C. Renaud Jr., M.B.A.President, CEO & DirectorN/DN/D1969
Dr. Susan Altschuller M.B.A., Ph.D.Chief Financial OfficerN/DN/D1982
Mr. Matthew CalistriVice President of Investor RelationsN/DN/DN/D
Mr. Scott M. Akamine J.D.Chief Legal Officer & Corporate Secretary444,74kN/D1985
Mr. Kenneth A. DiPietroChief Human Resources OfficerN/DN/D1959
Ms. Kathleen Tregoning M.A.Chief Corporate Affairs Officer600,79kN/D1971
Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di Cerevel Therapeutics Holdings, Inc. al 1 marzo 2024 è 6. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 7; diritti degli azionisti: 5; retribuzione: 6.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.